Cited by 749Smoking Behavior and CessationNicotinic Acetylcholine Receptors StudySubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.

Nicotine receptor partial agonists for smoking cessation

Open access

Cahill, K, Stead, LF, Lancaster, T·2007·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd006103.pub2PMC PMC6464943

Open this paper in CoChat — free account

Abstract

BACKGROUND: Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials are underway. OBJECTIVES: The primary objective of this review is to assess the efficacy and tolerability of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('varenicline' or 'cytisine' or 'Tabex' or 'nicotine receptor partial agonist') and 'smoking' in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, PsycINFO and CINAHL using MeSH terms and free text, and we contacted authors of trial reports for additional information where necessary. The last search was in October 2006. SELECTION CRITERIA: We included randomized controlled trials which compared the treatment drug with placebo. We also included comparisons with bupropion where available. We excluded trials which did not report a minimum follow-up period of six months from start of treatment. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of participants, the dose and duration of treatment, the outcome measures, the randomization procedure, concealment of allocation, and completeness of follow up. The main outcome measured was abstinence from smoking after at least six months from the beginning of treatment. We used the most rigorous definition of abstinence, and preferred biochemically validated rates where they were reported. Where appropriate we performed meta-analysis using the Mantel-Haenszel fixed-effect model. MAIN RESULTS: We found five trials of varenicline compared with placebo for smoking cessation; three of these also included a bupropion experimental arm. We also found one relapse prevention trial, comparing varenicline with placebo. The six trials covered 4924 participants, 2451 of whom used varenicline. We identified one trial of cytisine (Tabex) for inclusion. The pooled odds ratio (OR) for continuous abstinence at 12 months for varenicline versus placebo was 3.22 (95% confidence interval [CI] 2.43 to 4.27). The pooled OR for varenicline versus bupropion was 1.66 (95% CI 1.28 to 2.16). The main adverse effect of varenicline was nausea, which was mostly at mild to moderate levels and usually subsided over time. The two trials which tested the use of varenicline beyond the 12-week standard regimen found the drug to be well-tolerated and effective during long-term use. The one cytisine trial included in this review found that more participants taking cytisine stopped smoking compared with placebo at two-year follow up, with an OR of 1.77 (95% CI 1.30 to 2.40). AUTHORS' CONCLUSIONS: Varenicline increased the odds of successful long-term smoking cessation approximately threefold compared with pharmacologically unassisted quit attempts. In trials reported so far, more participants quit successfully with varenicline than with bupropion. The effectiveness of varenicline as an aid to relapse prevention has not been clearly established. The main adverse effect of varenciline is nausea, but this is mostly at mild to moderate levels and tends to reduce with habituation. There is a need for independent trials of varenicline versus placebo, to test the early findings. There is also a need for direct comparisons with nicotine replacement therapy, and for further trials with bupropion, to establish the relative efficacy of the treatments.Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006103.pub2

Cites

245 of 245 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,564
Self-citation
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Outcome criteria in smoking cessation trials: proposal for a common standard
West, R., Hajek, P., Stead, L., & Stapleton, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00995.x · Cited by 1,285
Self-citation
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Self-citation

Flagged first, then by citations

Show all 245 references

Research works printed but not linked: 13

Reeves K Watsky E Williams K Azoulay S Billing B Gong J The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54] Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA 2006
Benndorf, 1968, Results of smoking cessation treatment with cytisin (Tabex®), Das Deutsche Gesundheitwesen, 23, 2092
Benndorf, 1970, Smoking cessation treatment with cytisin (Tabex®): half-yearly outcomes for former smokers abstinent at four weeks from beginning of treatment, Das Deutsche Gesundheitwesen, 24, 774
Benndorf, 1969, Further reports on a double blind trial of the Bulgarian cytisine compound Tabex® on 1214 smokers wishing to quit and practical experience in conducting clinics for such smokers, Das Deutsche Gesundheitswesen, 24, 1135
Scharfenberg, 1971, Cytisine (Tabex®) as a treatment for smoking cessation, Das Deutsche Gesundheitwesen, 26, 463
Granatowicz, 1976, Smoking cessation through the use of cytisine and other therapy, World Smoking Health, 1, 8
Bacvarov, 1967, Smoking cessation through medication: remarks on G. Scharfenberg, E Winkelvoss and S. benndorf, Munch Med Wschr. 109 (1967) 1687-1689, Munchener Medizinische Wochenschrift, 109, 2663
Kempe, 1967, Observation about the Bulgarian medicine for smoking withdrawl Tabex, produced by Pharmachim-Sofia, Savr Med, 18, 355
Paun, 1968, [Smoking cessation with cytisine 'Tabex' tablets] [German], Sonderduck aus das deutsche Gesundheitwesen, 23, 2088
Paun, 1970, Tabex: registering and treatment of smokers with chronic bronchitis in the consultation against tobacco smoking - Berlin, Medico-Biologic Information, 3, 15
Stoyanov, 1972, [On the therapeutic effectiveness and tolerability of Tabex] [Bulgarian], Savremenna Medicina, 23, 30
Pfizer, An open-label, mullticentre study with follow-up evaluating the safety and efficacy of varenicline tartrate in comparison to transdermal nicotine patch for smoking cessation, www.controlled-trials.com/mRCT/trial/125463 (accessed 21/2/2006), ClinicalTrials.
Pfizer, A 12-week, double-blind, placebo-controlled, multicenter study with varenicline tartrate 1mg bid for smoking cessation, www.controlled-trials.com/mRCT/trial/123367 (accessed 21/2/2006), ClinicalTrials.

Sorted by citations

Items 401–500 of 749

Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non‐depressed adults: a retrospective cohort study
Carney, G., Bassett, K. L., Maclure, M., Taylor, S., & Dormuth, C. R. (2020) · Addiction · doi:10.1111/add.14951 · Cited by 15
Stage-based interventions for smoking cessation
Cahill, K., & Green, N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004492.pub3 · Cited by 15
Self-citation
Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial
Siddiqui, F., Kanaan, M. N., Croucher, R., Bauld, L., Fieroze, F., Kumar, P., Mazhar, L., Pandey, V., Jackson, C., Huque, R., et al. (2024) · Addiction · doi:10.1111/add.16515 · Cited by 14
The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada
von Wartburg, M., Raymond, V., & Paradis, P. E. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12363 · Cited by 14
Consenso sobre la atención sanitaria del tabaquismo en España
Guillem, F. C., Llivina, T. S., Torell, J. M. R., García, R. C., Ruiz, C. J., García-Aranda, V. L., Villalbí, J. R., Santos, M. Á. P., Monfort, J. S., & Santiago, A. L. (2009) · Revista Española de Salud Pública · doi:10.1590/s1135-57272009000200004 · Cited by 15
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Multimodal Smoking Cessation in a Real-Life Setting: Combining Motivational Interviewing With Official Therapy and Reduced Risk Products
Caponnetto, P., DiPiazza, J., Cappello, G. C., Demma, S., Maglia, M. G., & Polosa, R. (2019) · Tobacco Use Insights · doi:10.1177/1179173x19878435 · Cited by 14
Optimal use of smoking cessation pharmacotherapy
Mendelsohn, C. P. (2022) · Australian Prescriber · doi:10.18773/austprescr.2022.001 · Cited by 17
Exploring the barriers and facilitators to the uptake of smoking cessation services for people in treatment or recovery from problematic drug or alcohol use: A qualitative systematic review
Iyahen, E. O., Omoruyi, O. O., Rowa‐Dewar, N., & Dobbie, F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288409 · Cited by 13
Cardiovascular Prevention (IV) The Importance of Treating Tobacco Dependence
McRobbie, H. J., & Thornley, S. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60186-3 · Cited by 14
Interventions in Chronic Pain Management. 5. Approaches to Medication and Lifestyle in Chronic Pain Syndromes
Freedman, M. K., Saulino, M. F., Overton, E. A., Holding, M. Y., & Kornbluth, I. D. (2008) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.12.002 · Cited by 14
Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: A cross-study analysis
Hughes, J. R., Russ, C., Arteaga, C. E. Q., & Rennard, S. I. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.08.001 · Cited by 14
Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of these guidelines as an educational tool for neurologists. Endorsed by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Preventive Cardiovascular Nurses Association
Meschia, J. F., Bushnell, C., Boden-Albala, B. M., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Fornage, M., Goldstein, L. B., et al. (2014) · Cited by 15
Using the Social-Local-Mobile App for Smoking Cessation in the SmokeFreeBrain Project: Protocol for a Randomized Controlled Trial
Sánchez, F. J., Hernández, L. C., Núñez-Benjumea, F. J., González, M. M., Moreno-Conde, J., Parra-Calderón, C. L., Fernández-Luque, L., Hors-Fraile, S., Civit, A., Bamidis, P. D., et al. (2018) · JMIR Research Protocols · doi:10.2196/12464 · Cited by 14
Longitudinal Associations Between Smoking Cessation Medications and Alcohol Consumption Among Smokers in the International Tobacco Control Four Country Survey
McKee, S. A., Young‐Wolff, K. C., Harrison, E. L. R., Cummings, K. M., Borland, R., Kahler, C. W., Fong, G. T., & Hyland, A. J. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12041 · Cited by 14
Joint Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT) on the Diagnosis and Management of Chronic Obstructive Pulmonary Disease
Peces‐Barba, G., Barberà, J. A., Agustí, A. G. N., Casanova, C., Casas, A., Alonso, J. L. I., Jardim, J. R., Varela, V. L., Monsó, E., Montemayor, T., et al. (2008) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(08)60043-9 · Cited by 15
Lung cancer screening in Brazil: recommendations from the Brazilian Society of Thoracic Surgery, Brazilian Thoracic Association, and Brazilian College of Radiology and Diagnostic Imaging
Pereira, L. F. F., dos Santos, R. S., Bonomi, D. O., Franceschini, J., Santoro, I. L., Miotto, A., de Sousa, T. L. F., Chate, R. C., Hochhegger, B., Neto, A. G., et al. (2024) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230233 · Cited by 53
The potential of new nicotine and tobacco products as tools for people who smoke to quit combustible cigarettes – a systematic review of common practices and guidance towards a robust study protocol to measure cessation efficacy
Pluym, N., Burkhardt, T., Scherer, G., & Scherer, M. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01047-1 · Cited by 14
Depressive Symptoms Among Patients Receiving Varenicline and Bupropion for Smoking Cessation
Hong, A. S., Elrashidi, M. Y., Schroeder, D. R., & Ebbert, J. O. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.11.010 · Cited by 12
Systematic reviews on tobacco control from Cochrane and the Community Guide: different methods, similar findings
Rosen, L., & Noach, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.09.010 · Cited by 13
Varenicline induces manic relapse in bipolar disorder
Knibbs, N., & Tsoi, D. T.-Y. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.05.008 · Cited by 13
Varenicline for smoking cessation: Is it a heartbreaker?
Hays, J. T. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110804 · Cited by 13
Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers
Yardley, M. M., Mirbaba, M., & Ray, L. A. (2015) · CNS Drugs · doi:10.1007/s40263-015-0284-5 · Cited by 15
Does cigarette reduction while using nicotine replacement therapy prior to a quit attempt predict abstinence following quit date?
Lindson, N., Shinkins, B., West, R., Michie, S., & Aveyard, P. N. (2016) · Addiction · doi:10.1111/add.13330 · Cited by 13
Treatment of mild chronic obstructive pulmonary disease
Sin, D. D. (2008) · International Journal of COPD · doi:10.2147/copd.s3483 · Cited by 13
Update in Addiction Medicine for the Generalist
Gordon, A. J., Sullivan, L. E., Alford, D. P., Arnsten, J. H., Gourevitch, M. N., Kertesz, S. G., Kunins, H. V., Merrill, J. O., Samet, J. H., & Fiellin, D. A. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0133-4 · Cited by 12
Subsidized pharmacological treatment for smoking cessation by the Spanish public health system: A randomized, pragmatic, clinical trial by clusters
Minué-Lorenzo, C., Olano-Espinosa, E., del Cura-González, I., Vizcaíno-Sánchez, J., Guillem, F. C., Granados-Garrido, J., Ruiz-Pacheco, M., Gámez-Cabero, M. I., Martinez-Suberviola, F. J., & Serrano, M. E. S. (2019) · Tobacco Induced Diseases · doi:10.18332/tid/111368 · Cited by 13
The place of varenicline in smoking cessation treatment
Aveyard, P. N. (2008) · Thorax · doi:10.1136/thx.2008.096081 · Cited by 13
Smoking related attention alteration in chronic obstructive pulmonary disease-smoking comorbidity
Zeng, F., Hong, W., Zha, R., Li, Y., Chen, J., Liu, Y., Liu, H., Liu, M., Liu, M., Xu, F., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01964-6 · Cited by 13
Interventions for smokeless tobacco use cessation
Livingstone‐Banks, J., Vidyasagaran, A. L., Croucher, R., Siddiqui, F., Zhu, S., Kidwai, Z., Parkhouse, T., Mehrotra, R., & Siddiqi, K. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015314.pub2 · Cited by 13
Smoking cessation and serious mental illness: a service evaluation of a drop‐in stop smoking clinic on an acute in‐patient unit
Robson, D., Cole, F., Jalasi, S., Boojharut, B., Smith, S. M. R., Thompson, S., Jones, M., & Haddad, M. (2012) · Journal of Clinical Nursing · doi:10.1111/j.1365-2702.2012.04222.x · Cited by 14
Psycho- und Pharmakotherapie bei schädlichem Tabakgebrauch und -abhängigkeit
Batra, A., Petersen, K. U., Hoch, E., Mann, K. F., Kröger, C. B., Schweizer, C., Jähne, A., Rüther, T., Thürauf, N., & Mühlig, S. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-0037-1 · Cited by 13
Clinical challenges facing patient participation in cardiac rehabilitation: cigarette smoking
Gaalema, D. E., Khadanga, S., & Pack, Q. R. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2282026 · Cited by 14
Lung transplant and cystic fibrosis: what's new from the UK and France?
Noone, P. G. (2008) · Thorax · doi:10.1136/thx.2008.099622 · Cited by 12
Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats
Wu, J., Cippitelli, A., Zhang, Y., Debevec, G., Schoch, J., Ozawa, A., Yu, Y., Liu, H., Chen, W., Houghten, R. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01250 · Cited by 13
Cytisine for smoking cessation: A 40-day treatment with an induction period
Tinghino, B., Cardellicchio, S., Corso, F., Cresci, C., Pittelli, V., Principe, R., Siracusano, L., Zelano, G., Zagà, V., & Cattaruzza, M. S. (2024) · Tobacco Prevention & Cessation · doi:10.18332/tpc/187556 · Cited by 13
“Tobacco dependence treatment makes no sense because”…: Rebuttal of commonly-heard arguments against providing tobacco dependence treatment in the hospital setting
Balmford, J., Leifert, J. A., & Jaehne, A. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-1182 · Cited by 11
Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case–cross‐over study
Thomas, K. H., Davies, N. M., Taylor, A. E., Taylor, G. M. J., Gunnell, D., Martin, R. M., & Douglas, I. (2020) · Addiction · doi:10.1111/add.15338 · Cited by 10
Preguntas y respuestas en tabaquismo
Mavárez, J. D. Á., Villalona, R. M., Moreno, B. R., Calvo, G. S., César, E. C., & de Higes-Martínez, E. B. (2023) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100230 · Cited by 13
Pharmacologic risk factor management in peripheral arterial disease: A vade mecum for vascular surgeons
Rehring, T. F., Stolcpart, R. S., & Hollis, H. W. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.12.033 · Cited by 11
Tobacco smoking: options for helping smokers to quit.
Zwar, N. A., Mendelsohn, C. P., & RICHMOND, R. L. (2014) · PubMed · Cited by 11
Meanings of consumption and abandonment: understanding smoking cessation symbolism
Suarez, M. C. (2014) · BAR - Brazilian Administration Review · doi:10.1590/s1807-76922014000200006 · Cited by 11
Smoking cessation treatment for COPD smokers: the role of pharmacological interventions
Jimenez-Ruiz, C. A., & Fagerström, K. O. (2015) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2013.106 · Cited by 11
Secondary prevention of cardiovascular diseases: current state of the art
Hasenfuss, G. P. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0198 · Cited by 11
“Cold turkey” or pharmacotherapy: Examination of tobacco cessation methods tried among smokers prior to developing head and neck cancer
Khariwala, S. S., Rubin, N., Stepanov, I. S., Nollen, N. L., Ahluwalia, J. S., Nelson, H. H., & Hatsukami, D. K. (2019) · Head & Neck · doi:10.1002/hed.25708 · Cited by 11
Design of a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia
Tindle, H. A., Freiberg, M. S., Gnatienko, N., Blokhina, E. A., Cheng, D. M., Yaroslavtseva, T. V., Bendiks, S., Winter, M. R., Krupitsky, E. M., & Samet, J. H. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100625 · Cited by 11
Translational Research in Nicotine DependencePreprint
Turner, J. R., Gold, A. B., Schnoll, R. A., & Blendy, J. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a012153 · Cited by 11
Necessity and Readiness for Smoking Cessation Intervention in Dental Clinics in Japan
Ojima, M., Hanioka, T., & Tanaka, H. (2011) · Journal of Epidemiology · doi:10.2188/jea.je20110038 · Cited by 11
Smoking Cessation Interventions for Lung Cancer Patients
Carson‐Chahhoud, K., Usmani, Z. A., Robertson, T. A., Mysore, S., & Brinn, M. P. (2013) · Lung Cancer Management · doi:10.2217/lmt.12.55 · Cited by 11
Feasibility of Using E-mail Counseling as Part of a Smoking-Cessation Program
Polosa, R., Russo, C., Maria, A. D., Arcidiacono, G., Morjaria, J. B., & Piccillo, G. A. (2009) · Respiratory Care · doi:10.4187/respcare.09541033 · Cited by 10
Quitting Failure and Success With and Without Using Medication: Latent Classes of Abstinence and Adherence to Nicotine Monotherapy, Combination Therapy, and Varenicline
McCarthy, D. E., & Versella, M. V. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty157 · Cited by 10
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder
Moerke, M. J., McMahon, L. R., & Wilkerson, J. L. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018028 · Cited by 11
Contribution of Animal Models and Preclinical Human Studies to Medication Development for Nicotine Dependence
Markou, A., Chiamulera, C., & West, R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00026-6 · Cited by 10
Pregnancy Outcome after Varenicline Exposure in the First Trimester
Kaplan, Y. C., Dündar, N. O., Kasap, B., & Karadas, B. (2014) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2014/263981 · Cited by 11
Pharmacological treatment of addiction
Watson, B. J., & Lingford-Hughes, A. R. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.04.008 · Cited by 10
Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence
Leyro, T. M., Crew, E., Bryson, S. W., Lembke, A., Bailey, S. R., Prochaska, J. J., Henriksen, L., Fortmann, S. P., Killen, J. D., Killen, D. T., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010960 · Cited by 10
Neuregulin signaling pathway in smoking behavior
Gupta, R., Qaiser, B., He, L., Hiekkalinna, T., Zheutlin, A. B., Therman, S., Ollikainen, M., Ripatti, S., Perola, M., Salomaa, V. V., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.183 · Cited by 11
The smoking cessation drug varenicline improves deficient P20–N40 inhibition in DBA/2 mice
Wildeboer, K. M., & Stevens, K. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.07.001 · Cited by 9
Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database
Kotz, D., Simpson, C. R., Viechtbauer, W., van Schayck, O. C. P., West, R., & Sheikh, A. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005281 · Cited by 9
Determinants of Smoking Cessation Outcomes and Reasons for Relapse in Patients Admitted to a Smoking Cessation Outpatient Clinic in Turkey
Acar, T., Gallagher, C., Gören, Y., Erbas, B., & Özkara, A. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21030310 · Cited by 9
Potential Conflict of Interest and Bias in the RACGP's Smoking Cessation Guidelines: Are GPs Provided with the Best Advice on Smoking Cessation for their Patients?
MacKenzie, R., & Rogers, W. (2015) · Public Health Ethics · doi:10.1093/phe/phv010 · Cited by 9
Relative Potency of Varenicline or Fluvoxamine to Reduce Responding for Ethanol Versus Food Depends on the Presence or Absence of Concurrently Earned Food
Ginsburg, B. C., & Lamb, R. J. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12285 · Cited by 9
2013 Update in addiction medicine for the generalist
Gordon, A. J., Bertholet, N., McNeely, J., Starrels, J. L., Tetrault, J. M., & Walley, A. Y. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-18 · Cited by 8
Assessment of cost‐effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD
Anraad, C., Cheung, K. L., Hiligsmann, M., Coyle, K., Coyle, D., Owen, L., West, R., de Vries, H., Evers, S., & Pokhrel, S. (2018) · Addiction · doi:10.1111/add.14093 · Cited by 8
Partial agonists for α4β2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects
Chen, Y., Broad, L. M., Phillips, K. G., & Zwart, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01628.x · Cited by 9
Rauchen und Nikotinabhängigkeit in Deutschland
Hoch, E., Mühlig, S., Nowak, D., & Wïttchen, H. (2008) · Zeitschrift für Klinische Psychologie und Psychotherapie · doi:10.1026/1616-3443.37.1.1 · Cited by 9
Atención y craving o ganas compulsivas. Avances en su conceptualización y su implicación en la prevención de recaídas
Blasco, J., Martı́nez-Raga, J., Carrasco, E., & Didia-Attas, J. (2008) · Adicciones · doi:10.20882/adicciones.259 · Cited by 9
Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates
Jacobs, D. S., Barkin, C. E., Kohut, M. R., Bergman, J., & Kohut, S. J. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.09.008 · Cited by 9
Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice
Lee, L. J., Li, Q., Bruno, M., Emir, B., Murphy, B., Shah, S., Reynolds, M. W., Marchant, N., & Park, P. W. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0858-y · Cited by 10
Vascular risk screening: possible or too much, too soon?
Wierzbicki, A. S., & Reynolds, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02111.x · Cited by 9
Documento de posicionamiento de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) ante las estrategias de reducción del daño del tabaco
Ruiz, C. A. J., Solano-Reina, S., de Higes-Martínez, E., Cabrera-César, E., Sandoval-Contreras, R., de Granda‐Orive, J. I., Riesco-Miranda, J. A., Miñana, J. S.-C., Lorza-Blasco, J. J., Martínez-Muñiz, M. Á., et al. (2022) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100175 · Cited by 10
Challenges and perspectives of tobacco cessation in special groups of patients and populations
Tsikrika, S., Dai, S., Dilektaşlı, A. G., Katsaounou, P. A., & Dağlı, E. (2023) · Breathe · doi:10.1183/20734735.0224-2022 · Cited by 9
Smoking cessation pharmacotherapy; varenicline or bupropion?
Rahimi, F., Massoudifar, A., & Rahimi, R. (2024) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-024-00539-6 · Cited by 8
Brazilian Society of Angiology and Vascular Surgery guidelines on peripheral artery disease
Erzinger, F. L., Polimanti, A. C., Pinto, D. M., Murta, G. B., Cury, M. V. M., da Silva, R. B., Biagioni, R. B., Belczak, S. Q., Joviliano, E. É., de Araújo, W. J. B., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202300592 · Cited by 10
Recommendations on interventions for tobacco smoking cessation in adults in Canada
Thombs, B. D., Traversy, G., Reynolds, D. L., Lang, E., Groulx, S., & Wilson, B. J. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241584 · Cited by 11
Nephrotoxic effects of varenicline as the most effective drug used for smoking cessation: a preliminary experimental study
Koç, A., Erken, H. A., Koçak, F. E., Yay, A., Güçlü, A., Sarı, E., Şimşek, H., Önder, G. Ö., & Genç, O. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-0949-5 · Cited by 8
Inequity in smoking cessation clinical trials testing pharmacotherapies: exclusion of smokers with mental health disorders
Talukder, S. R., Lappin, J., Boland, V. C., McRobbie, H. J., & Courtney, R. J. (2021) · Tobacco Control · doi:10.1136/tobaccocontrol-2021-056843 · Cited by 8
A narrative review of epidemiology and prevention of lung cancer: sex/gender differences?
Baldacci, S., Maio, S., Meschi, C., Chimera, D., Tagliaferro, S., Angino, A. A., Silvi, P., Pistelli, F., & Carrozzi, L. (2022) · Precision Cancer Medicine · doi:10.21037/pcm-21-54 · Cited by 8
Spirometry and Smoking Cessation in Primary Care: The ESPIROTAB STUDY, A Randomized Clinical Trial
Rodríguez-Álvarez, M. D. M., Roca-Antonio, J., Martínez-González, S., Vilà-Palau, V., Chacón, C., Ortega-Roca, A., Borrell-Thió, E., Erazo, S., Almirall, J., & Torán‐Monserrat, P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114557 · Cited by 8
Mifepristone decreases nicotine intake in dependent and non-dependent adult rats
Chellian, R., Behnood‐Rod, A., & Bruijnzeel, A. W. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241230255 · Cited by 7
“Hike up yer Skirt, and Quit.” What Motivates and Supports Smoking Cessation in Builders and Renovators
Bondy, S. J., & Bercovitz, K. L. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10020623 · Cited by 8
Guideline Watch (April 2007): Practice Guideline for the Treatment of Patients With Substance Use Disorders, 2nd Edition
Connery, H. S., & Kleber, H. D. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.2.foc163 · Cited by 8
A bibliometric analysis of clinical study literature of traditional Chinese medicine therapies for smoking cessation
Wang, J., Wang, M., Liu, S., Du, X.-F., Han, M., Liu, J., Qin, W., Chen, B., van Haselen, R. A., & Liu, J. (2018) · Tobacco Induced Diseases · doi:10.18332/tid/86330 · Cited by 8
Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan
Madae’en, S., Obeidat, N. A., & Adeinat, M. (2020) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-020-00270-y · Cited by 8
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers
Grodin, E. N., Burnette, E. M., Green, R., Lim, A. C., Miotto, K. A., & Ray, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108825 · Cited by 8
Age-Related Interactions on Key Theoretical Determinants of Smoking Cessation: Findings from the ITC Four Country Smoking and Vaping Surveys (2016–2020)
Grande, M. R. L., Borland, R., Yong, H., McNeill, A. D., Fong, G. T., & Cummings, K. M. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab230 · Cited by 8
A smoking cessation induction intervention via virtual reality headset during a dental cleaning: protocol for a randomized controlled trial
Borrelli, B., Endrighi, R., Jurasic, M. M., Hernandez, H., Jones, E. A., Ospina, J., Cabral, H., Quintiliani, L. M., & Werntz, S. (2022) · BMC Public Health · doi:10.1186/s12889-022-13427-y · Cited by 9
Evidence and decision making: tobacco control policy and legislation in Vietnam
Higashi, H., Khuong, T. A., Ngo, A. D., & Hill, P. (2012) · The International Journal of Health Planning and Management · doi:10.1002/hpm.2135 · Cited by 8
Effectiveness of varenicline and counselling for smoking cessation in an observational cohort study in China
Jiang, B., He, Y., Zuo, F., Wu, L., Liu, Q., Zhang, L., Zhou, C., Cheng, K. K., Chan, S. S. C., & Lam, T. H. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009381 · Cited by 8
The efficacy of varenicline in achieving abstinence among waterpipe tobacco smokers – study protocol for a randomized controlled trial
Zahid, R., Dogar, O. F., Mansoor, S., Khan, A., Kanaan, M. N., Jawad, M., Ahluwalia, J. S., & Siddiqi, K. (2017) · Trials · doi:10.1186/s13063-016-1761-y · Cited by 8
The Effect of Varenicline Administration on Cannabis and Tobacco Use in Cannabis and Nicotine Dependent Individuals ? A Case-Series
Newcombe, D. A. L. (2015) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000222 · Cited by 7
Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies
Pintarelli, G., Galvan, A., Pozzi, P., Noci, S., Pasetti, G., Sala, F., Pastorino, U., Boffi, R., & Colombo, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-16946-6 · Cited by 8
Cost‐effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD
Huber, M. B., Präger, M., Coyle, K., Coyle, D., Lester‐George, A., Trapero‐Bertran, M., Németh, B., Cheung, K. L., Stark, R. G., Vogl, M., et al. (2017) · Addiction · doi:10.1111/add.14062 · Cited by 7
Nicotine vaccines for smoking cessation
Hatsukami, D., Cahill, K., & Stead, L. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007072 · Cited by 8
Self-citation
Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
Mistry, H., Enderby, J., Court, R. A., Al-Khudairy, L., Nduka, C. U., Meléndez‐Torres, G. J., Taylor‐Phillips, S., Clarke, A., & Uthman, O. A. (2022) · Health Technology Assessment · doi:10.3310/qovk6659 · Cited by 7
Smoking cessation intervention in Australian general practice: a secondary analysis of a cluster randomised controlled trial
Gobarani, R. K., Zwar, N. A., Russell, G. M., Abramson, M. J., Bonevski, B., Holland, A. E., Paul, E. M., Cox, N. S., Wilson, S., & George, J. (2021) · British Journal of General Practice · doi:10.3399/bjgp.2020.0906 · Cited by 7
Differences in the effectiveness of individual-level smoking cessation interventions by socioeconomic status
Theodoulou, A., Fanshawe, T. R., Leavens, E. L. S., Theodoulou, E., Wu, A. D., Heath, L., Stewart, C., Nollen, N. L., Ahluwalia, J. S., Butler, A. R., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015120.pub2 · Cited by 13
Fumador internado? – A intervenção apropriada
Pamplona, P., & Pina, J. (2007) · Revista Portuguesa de Pneumologia · doi:10.1016/s2173-5115(07)70374-3 · Cited by 7
A Clinical Imperative: Assisting Patients Who Smoke to Reduce Their Risk of Cardiovascular Disease
Bullen, C., Whittaker, R., McRobbie, H. J., & Fagerström, K. O. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.06525.x · Cited by 7
Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study
Gratziou, C., Gourgoulianis, K. I., Argyropoulou-Pataka, P., Sykara, G. D., Messig, M., & Raju, S. (2012) · Tobacco Induced Diseases · doi:10.1186/1617-9625-10-1 · Cited by 7

Authors: Cahill, K., Stead, L., & Lancaster, T.
Affiliations: University of Oxford (GB)
University of Bristol (GB)
Venue: Cochrane Database of Systematic Reviews
Publisher: John Wiley & Sons, Ltd
Published: 2007-01-24
Issue: 1
Pages: CD006103-CD006103
ISSN: 1361-6137 (ISSN-L)
DOI: 10.1002/14651858.cd006103.pub2
PMC: PMC6464943
OpenAlex: W2116514043
Cited by: 747
References: 245
Citations by year: 2025: 15 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 41 · 2020: 21 · 2019: 36 · 2018: 33 · 2017: 49 · 2016: 28 · 2015: 41 · 2014: 49 · 2013: 57 · 2012: 68
Type: reference entry
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords: nicotine receptor partial agonist, smoking cessation, cytisine, varenicline, nicotine replacement therapy, bupropion, nicotine patch, smoking abstinence, nicotine withdrawal symptoms, smoking satisfaction, nicotine dependence, nicotine antagonists
MeSH terms: Varenicline, Quinolizidine Alkaloids, Alkaloids, Azocines, Benzazepines, Humans, Nicotine, Quinolizines, Quinoxalines, Randomized Controlled Trials as Topic, Smoking Cessation, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nicotine receptor partial agonists for smoking cessation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks